SCHEMBL342622

SCHEMBL342622

CCCCCC(CC)(CC)/C(=C/C(=O)O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
CES2 O00748 1/20 0.34
AKR1B1 P15121 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
PPARG P37231 3/20 0.32
PPARD Q03181 3/20 0.32
PPARA Q07869 3/20 0.32
GGPS1 O95749 2/20 0.32
TSHR P16473 2/20 0.32
GPR84 Q9NQS5 2/20 0.32
HDAC11 Q96DB2 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
FDPS P14324 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SLC22A6 Q4U2R8 1/20 0.32
SLC22A8 Q8TCC7 1/20 0.32
TLR2 O60603 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342623 1.00 EP300 (0.35) EP300CYP4F2CYP4A11CES2AKR1B1
SCHEMBL8676391 1.00 EP300 (0.35) EP300CYP4F2CYP4A11CES2AKR1B1
Maleic Acid SCHEMBL16685175 0.95 HCAR2 (0.40) HCAR2TDP1
SCHEMBL4016866 0.84 EP300 (0.32) EP300AKR1B1HCAR2ALOX15
SCHEMBL4016868 0.84 EP300 (0.32) EP300AKR1B1HCAR2ALOX15
SCHEMBL10008914 0.79 EP300 (0.35) EP300CES2AKR1B1HCAR2PPARG
SCHEMBL9513413 0.77 EP300 (0.39) EP300CES2AKR1B1PPARGPPARD
SCHEMBL2138523 0.74 CYP4F2 (0.42) CYP4F2CYP4A11CES2AKR1B1PPARG
SCHEMBL3417789 0.74 CYP4F2 (0.42) CYP4F2CYP4A11CES2AKR1B1PPARG
SCHEMBL10481805 0.74 ACLY (0.36) EP300AKR1B1HCAR2ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112754958-B V73E modified shielding agent, preparation method and application thereof in skin care products 上海迪摩化学科技有限公司 2022-10-18 CN claimed
CN-112754958-A V73E modified shielding agent, preparation method and application thereof in skin care products 上海迪摩化学科技有限公司 2021-05-07 CN claimed
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER SOL-GEL TECHNOLOGIES LTD. (IL) 2012-12-20 US claimed
EP-2324812-A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients Sol-Gel Technologies Ltd. (IL) 2011-05-25 EP claimed
EP-1368057-B1 METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN TORREY PINES INST (US) 2009-08-26 EP claimed
US-7229621-B2 Method to enhance the immunogenicity of an antigen TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2007-06-12 US claimed
EP-1071411-B1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INST (US) 2007-03-14 EP claimed
EP-1179024-B1 ORGANOBORANE AMINE COMPLEX INITIATOR SYSTEMS AND POLYMERIZABLE COMPOSITIONS MADE THEREWITH 3M INNOVATIVE PROPERTIES CO (US) 2005-03-16 EP claimed
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water SOL-GEL TECHNOLOGIES LTD. (IL) 2005-02-17 US claimed
EP-1071411-A4 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INST (US) 2004-12-08 EP claimed
WO-2003034979-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2003-05-01 WO claimed
WO-2002074332-A2 METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN LANCELL, LLC (US) 2002-09-26 WO claimed
US-20020064541-A1 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients SOL-GEL TECHNOLOGIES LTD. (IL) 2002-05-30 US claimed
WO-2001080823-A2 COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TROPICAL ACTIVE INGREDIENTS SOL-GEL TECHNOLOGIES LTD. (IL) 2001-11-01 WO claimed
US-20010024649-A1 Method to enhance the immunogenicity of an antigen TORREY PINES INSTITUTE FOR MOLECULAR STUDIES 2001-09-27 US claimed
US-6210672-B1 TOPICAL ADMINISTRATION OF AN ANTIGEN OR A PORTION THEREOF IN CONJUNCTION WITH AN ENHANCER OF SKIN PENETRATION AND AN INDUCER OF LANGERHANS CELL MIGRATION. TORREY PINES INSTITUTE FOR MOLECULAR STUDIES 2001-04-03 US claimed
EP-1071411-A1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2001-01-31 EP claimed
WO-1999053912-A1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1999-10-28 WO claimed
EP-0702059-B1 Crosslinked polymer-powder compositions WACKER CHEMIE GMBH (DE) 1996-12-18 EP claimed
EP-0702059-A1 Crosslinked polymer-powder compositions Wacker-Chemie GmbH (DE) 1996-03-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120321685-A1 COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER GNG2, COG5, SQLE EP300 1040/4885CYP4F2 4293/4885CYP4A11 1493/4885
US-20010024649-A1 Method to enhance the immunogenicity of an antigen CD69, CD74, LY96 EP300 1330/4885CYP4F2 2949/4885CYP4A11 3220/4885
US-20050037087-A1 Compositions containing oils having a specific gravity higher than the specific gravity of water GNG2, COG5, SQLE EP300 1040/4885CYP4F2 4293/4885CYP4A11 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.